ATLAS: A Randomized, Double-blind, Placebo-controlled Phase 3 Study of JNJ-56021927 in Subjects With High-risk, Localized or Locally Advanced Prostate Cancer Receiving Treatment With Primary Radiation Therapy
The purpose of this study is to determine if apalutamide plus gonadotropin releasing hormone
(GnRH) agonist in participants with high-risk, localized or locally advanced prostate cancer
receiving primary radiation therapy results in an improvement of metastasis-free survival.
View this trial on ClinicalTrials.gov
Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.
These resources are provided in partnership with the
Canadian Cancer Society